Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity

Bibliography

• Hilgard P, Klenner T, Stekar J, Unger C. Alkylphosphocholines: a new class of membrane-active anticancer agents. Cancer Chemother Pharmacol 1993;32:90-5
   PubMed Web of Science ®Google Scholar
• Kondapaka SB, Singh SS, Dasmahapatra GP, Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2(11):1093-103
   PubMed Web of Science ®Google Scholar
• Vink SR, Schellens JHM, van Blitterswijk WJ, Verheij M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs 2005;23:279-86
   PubMed Web of Science ®Google Scholar
• Fleer EAM, Unger C, Kim D-J, Eibl H. Metabolism of other phospholipids and analogs in neoplastic cells. Lipids 1987;22:856-61
   PubMed Web of Science ®Google Scholar
• Stekar J, Hilgard P, Klenner T, A second generation of alkylphospholipids with high antineoplastic activity [abstract 1996]. Proc Am Assoc Cancer Res 1993;34:335
   Google Scholar
• Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009;11:102-10
   PubMed Web of Science ®Google Scholar
• Available from: http://www.cancer.org/Research/CancerFactsFigures/ColorectalCancerFactsFigures/colorectal-cancer-facts-figures-2011-2013-page [Last accessed 30 December 2011]
   Google Scholar
• Available from: http://www.cancer.org/Cancer/MultipleMyeloma/DetailedGuide/multiple-myeloma-references [Last accessed 30 December 2011]
   Google Scholar
• Hideshima T, Catley L, Yasui H, Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006;107(10):4053-62
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim TS, Kwan BR, Evaluation of anticancer drug sensitivity and gene expression patterns of a novel Akt inhibitor, perifosine in gastric cancer (poster). AACR
   Google Scholar
• Rahmani M, Reese E, Dai Y, Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005;65:2422-32
   PubMed Web of Science ®Google Scholar
• Voboril R, Weberova-Voborilova J. Constitutive NF- kappaB activity in colorectal cancer cells: impact on radiation-induced NF-kappa B activity, radiosensitivity, and apoptosis. Neoplasma 2006;53(6):518-23
   PubMed Web of Science ®Google Scholar
• Leleu X, Eeckhoute J, Jia X, Targeting NF- kappa B in Waldenstrom macroglobulinemia. Blood 2008;111(10):5068-77
   PubMed Web of Science ®Google Scholar
• Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309
   PubMed Web of Science ®Google Scholar
• Poradosu E, Lemmon M, Keleti D. Perifosine selectively inhibits binding of Akt PH domain to PtdIns(3,4)P2 [abstract 1645]. 98th AACR Annual Meeting; 2007
   Google Scholar
• Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010;1805:167-80
   PubMed Web of Science ®Google Scholar
• Lin Y, Bai L, Chen W, The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 2010;14:45-55
   PubMed Web of Science ®Google Scholar
• Voboril R, Hochwald SN, Li J, Inhibition of NF-kappa B augments sensitivity to 5 fluorouracil/folinic acid in colon cancer. J Surg Res 2004;120:178-88
   PubMed Web of Science ®Google Scholar
• NCT00398879: a randomized placebo-controlled study of perifosine in combination with single agent chemotherapy for metastatic cancer patients. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00398879?term=nct00398879&rank=1 [Last accessed 16 December 2011]
   Google Scholar
• Bendell JC, Nemunaitis J, Vukelja ST, Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 2011;36:1980
   Google Scholar
• Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927-37
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-18
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Anderson KC. Novel therapeutic approaches for multiple myeloma. Immunol Rev 2003;194:164-76
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Akiyama M, Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-4
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Hayashi T, Antitumor activity of lysophosphatidic acid acyltransferase (LPAAT)-inhibitors, a novel class of agents, in multiple myeloma. Cancer Res 2003;63:8428-36
   PubMed Web of Science ®Google Scholar
• Romagnoli M, Trichet V, David C, Significant impact of survivin on myeloma cell growth. Leukemia 2007;21:1070-8
   PubMed Web of Science ®Google Scholar
• Hideshima T, Catley L, Raje N, Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 2007;138:783-91
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Dabrowski R, Weimann A, In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines. Invest New Drugs 2010; published online 16 November 2010; doi:10.1007/s10637-010-9576-2.
   PubMed Web of Science ®Google Scholar
• Crul M, Rosing H, de Klerk GJ, Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002;38:1615-21
   PubMed Web of Science ®Google Scholar
• NCT00398697: Phase 1 Trial of the Combination of Perifosine and Gemcitabine. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00398697?term=perifosine+102&rank=1 [Last accessed 16 December 2011]
   Google Scholar
• NCT00005794: A Phase I Trial of Perifosine on a Loading Dose/Maintenance Dose Schedule in Patients With Advanced Cancer. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT00005794?term=perifosine&spons=NCI&phase=0&rank=4 [Last accessed 16 December 2011]
   Google Scholar
• Van Ummerson L, Binger K, Volkman J, A Phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Can Res 2004;10:7450-6
   PubMed Web of Science ®Google Scholar
• NCT01048580: a Phase I study of perifosine + capecitabine for patients with advanced colon cancer. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01048580?term=NCT01048580&rank=1 [Last accessed 16 December 2011]
   Google Scholar
• Greco FA, Infante J, Burris H, Safety and pharmacokinetic (PK) study of perifosine plus capecitabine (P-CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). Presented at ASCO; 2010
   Google Scholar
• Unger C, Berdel W, Hanauske AR, First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. Eur J Cancer 2010;46(5):920-5
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O’Callaghan CJ, Karapetis CS, Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8
   PubMed Web of Science ®Google Scholar
• NCT01097018: a Phase III randomized study to assess the efficacy and safety of perifosine plus capecitabine versus placebo plus capecitabine in patients with refractory advanced colorectal cancer. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01097018?term=NCT01097018&rank=1 [Last accessed 16 December 2011]
   Google Scholar
• NCT00375791: an open-label Phase II study of the safety and efficacy of perifosine alone and in combination with dexamethasone for patients with relapsed or relapsed/refractory multiple myeloma. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00375791?term=NCT00375791&rank=1 [Last accessed 16 December 2011]
   Google Scholar
• Richardson PG, Lonial S, Jakubowiak A, Multi-center phase ll study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma: promising activity as combination therapy with manageable toxicity [abstract 1164]. Blood 2007;110:353
   Google Scholar
• NCT00415064: an open-label Phase I study of the safety of perifosine in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00415064?term=NCT00415064&rank=1 [Last accessed 16 December 2011]
   Google Scholar
• Jakubowiak A, Richardson PG, Zimmerman T, Final phase I results of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (MM). Blood 2010;116:abstract 3064
   Google Scholar
• NCT00401011: an open-label Phase I/II study of the safety and efficacy of perifosine and bortezomib with or without dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with bortezomib. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00401011?term=NCT00401011&rank=1 [Last accessed 16 December 2011]
   Google Scholar
• Richardson PG, Wolf J, Jakubowiak A, Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol 2011; Published online on 11 October 2011; DOI:10.1200/JCO.2010.33.9788.
   Web of Science ®Google Scholar
• NCT01002248: a Phase III randomized study to assess the efficacy and safety of perifosine added to the combination of bortezomib and dexamethasone in multiple myeloma patients. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT01002248?term=NCT01002248&rank=1 [Last accessed 16 December 2011]
   Google Scholar
• NCT00422656: a Phase II study of perifosine in patients with relapsed/refractory Waldenstrom's macroglobulinemia. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00422656?term=Dana+Farber+06-077&rank=1 [Last accessed 16 December 2011]
   Google Scholar
• Treon S, Hunter P, Matous R, Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007;13:3320-5
   PubMed Web of Science ®Google Scholar